EBR Systems Receives Final Approval for NTAP Reimbursement; Shares Up 7%

MT Newswires Live
2025/08/05

EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services confirmed approval for its Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy (WiSE CRT) System under the New Technology Add-On Payment (NTAP) scheme for Medicare inpatients, according to a Tuesday filing with the Australian bourse.

The confirmation ensures a maximum reimbursement rate of up to $41,145, based on an average WiSE selling price of $63,300, in addition to Diagnosis Related Group payments for procedure and device costs, the filing said.

The NTAP reimbursement will remain in effect for three years, according to the filing.

Shares rose more than 7% in morning trade on Tuesday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10